- Home
- GLU vs GNLX Comparison
GLU vs GNLX Comparison
Compare GLU & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLU
- GNLX
- Stock Information
- Founded
- GLU 2004
- GNLX 2001
- Country
- GLU United States
- GNLX United States
- Employees
- GLU N/A
- GNLX N/A
- Industry
- GLU Finance/Investors Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- GLU Finance
- GNLX Health Care
- Exchange
- GLU Nasdaq
- GNLX Nasdaq
- Market Cap
- GLU 99.4M
- GNLX 110.9M
- IPO Year
- GLU N/A
- GNLX 2023
- Fundamental
- Price
- GLU $17.63
- GNLX $3.09
- Analyst Decision
- GLU
- GNLX Strong Buy
- Analyst Count
- GLU 0
- GNLX 4
- Target Price
- GLU N/A
- GNLX $17.75
- AVG Volume (30 Days)
- GLU 12.4K
- GNLX 137.5K
- Earning Date
- GLU 01-01-0001
- GNLX 08-13-2025
- Dividend Yield
- GLU 8.60%
- GNLX N/A
- EPS Growth
- GLU N/A
- GNLX N/A
- EPS
- GLU 0.62
- GNLX N/A
- Revenue
- GLU N/A
- GNLX N/A
- Revenue This Year
- GLU N/A
- GNLX N/A
- Revenue Next Year
- GLU N/A
- GNLX N/A
- P/E Ratio
- GLU $22.50
- GNLX N/A
- Revenue Growth
- GLU N/A
- GNLX N/A
- 52 Week Low
- GLU $11.61
- GNLX $1.60
- 52 Week High
- GLU $15.40
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- GLU 71.86
- GNLX 56.10
- Support Level
- GLU $16.98
- GNLX $2.75
- Resistance Level
- GLU $17.35
- GNLX $3.17
- Average True Range (ATR)
- GLU 0.21
- GNLX 0.23
- MACD
- GLU 0.06
- GNLX -0.00
- Stochastic Oscillator
- GLU 93.64
- GNLX 56.94
About GLU Gabelli Global Utility of Beneficial Ownership
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.